Immunic, Inc. (IMUX)

Market Cap	114.40M
Revenue (ttm)	n/a
Net Income (ttm)	-96.90M
Shares Out	90.08M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,123,176
Open	1.240
Previous Close	1.180
Day's Range	1.202 - 1.390
52-Week Range	0.920 - 2.110
Beta	1.87
Analysts	Strong Buy
Price Target	12.67 (+897.64%)
Earnings Date	Mar 4, 2025

About IMUX

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 77
• Stock Exchange: NASDAQ
• Ticker Symbol: IMUX
• Website: https://imux.com

Analyst Forecast

According to 6 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price forecast is $12.67, which is an increase of 897.64% from the latest price.

Price Target

$12.67

(897.64% upside)

Analyst Consensus: Strong Buy